Document Detail


Combination therapy in the management of mixed dyslipidaemia.
MedLine Citation:
PMID:  18324928     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Whilst statin monotherapy is often sufficient to reach LDL-C goals, treatment may not reach all lipid goals in individuals with mixed dyslipidaemia typically associated with metabolic syndrome or type 2 diabetes. Double or triple combination therapy, which provides the opportunity to address multiple lipid abnormalities simultaneously, may be required to achieve targets in some patients. Addition of fenofibrate or niacin (nicotinic acid) to statin therapy is likely to be the first option, as recommended by national treatment guidelines; omega-3 fatty acids may also be useful. Careful monitoring is required when adding additional agents given the increased potential for drug interactions and side effects.
Authors:
C P Cannon
Related Documents :
9867158 - Scintigraphic localization of lymphatic leakage site after oral administration of iodin...
11918018 - Recovery of streams from episodic acidification in northern sweden.
20567608 - Fluorophilicity of alkyl and polyfluoroalkyl 1 nicotinic acid ester prodrugs.
7357948 - Cardiopulmonary effects of fenoterol and salbutamol aerosols.
8896028 - Consumption of amino acids by bovine preimplantation embryos.
23384618 - Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of internal medicine     Volume:  263     ISSN:  1365-2796     ISO Abbreviation:  J. Intern. Med.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-07     Completed Date:  2008-04-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8904841     Medline TA:  J Intern Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  353-65     Citation Subset:  IM    
Affiliation:
Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. cpcannon@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use*
Cardiovascular Diseases / epidemiology,  prevention & control*
Cholesterol, LDL / drug effects*
Diabetes Mellitus, Type 2 / drug therapy
Drug Administration Routes
Drug Therapy, Combination
Dyslipidemias / drug therapy*,  metabolism
Fatty Acids, Omega-3 / therapeutic use
Female
Humans
Male
Metabolic Syndrome X / drug therapy
Niacin / therapeutic use*
Procetofen / therapeutic use*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Cholesterol, LDL; 0/Fatty Acids, Omega-3; 49562-28-9/Procetofen; 59-67-6/Niacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epi...
Next Document:  High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in ...